Testing a radiation drug for meningioma that has come back
Original title: Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug that carries radiation to meningioma tumors that grew back after earlier treatment.
Who this trial is for. This trial is for adults with a grade 1 to 3 meningioma inside the brain that is growing again after past treatment. People are placed at random into one of two groups. One group gets the drug [177Lu]Lu-DOTATATE. The other group gets the usual care for this tumor.
Where it stands. The trial is measuring how well [177Lu]Lu-DOTATATE works compared to usual care. The source does not report any results. The answer is not in yet.
What this means, and what it doesn't
What it could mean: For now, this drug is only available inside a study like this one. Someone whose meningioma has come back could ask their care team about it. The care team can say if it is a fit and if a site is within reach.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Joining one is not a guarantee that it will help you. It is not a promise of a cure. Only the trial team decides who can take part.
Source: ClinicalTrials.gov, September 8, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.